27 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 Grifols Partnership is a specialized Contract Development and Manufacturing Organization (CDMO) dedicated to the development and production of high quality sterile injectable solutions, with a strong focus on small molecule parenteral products. Leveraging more than 85 years of Grifols’ global pharmaceutical expertise, the CDMO division combines deep technical know how, state of the art industrial capabilities, and a robust quality culture to deliver reliable, end to end manufacturing solutions for customers worldwide. As a parenteral CDMO, Grifols Partnership offers comprehensive support across the product lifecycle— from formulation development and technology transfer to clinical and commercial scale manufacturing. The organization provides flexible and efficient solutions for small volume and large volume parenterals, including intravenous solutions, diluents for reconstitution, and other complex sterile drug products. Manufacturing capabilities cover both glass vials (5 mL to 500 mL) and polypropylene IV bags (50 mL to 1000 mL), supported by advanced filling technologies, automatic inspection systems, and laser etched vial identification that ensures full traceability. Grifols Partnership operates through two EMA and FDA approved facilities in Spain located in Barcelona and Murcia, including parametric release approval. These facilities host modern FFS lines, high capacity autoclaves for terminal sterilization, automated inspection systems, and dedicated laboratories for R&D and quality control. This infrastructure enables the manufacture of a wide range of parenteral formats under stringent GMP and pharmacopeial standards, ensuring the highest levels of safety, consistency, and compliance. A key differentiator of Grifols Partnership is its ability to draw on the broader resources of the Grifols organization, including extensive plasma derived product expertise, global supply chain robustness, and decades of experience in intravenous therapies. The CDMO division has a strong track record of supporting small, mid size, and large pharmaceutical companies, offering flexibility, customized solutions, and a collaborative approach to project execution. With a commitment to quality, innovation, and long term partnerships, Grifols Partnership positions itself as a trusted CDMO for companies seeking reliable, high value parenteral manufacturing services. Its combination of technical excellence, regulatory strength, and customer centric service makes it an ideal partner for bringing sterile injectable products successfully to market. COMPANY PROFILE
RkJQdWJsaXNoZXIy MjY2OTA4MA==